Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015 (2015), Article ID 206302, 8 pages
http://dx.doi.org/10.1155/2015/206302
Review Article

Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis

1Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
2Department of Infectious Diseases, The Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China

Received 16 December 2014; Revised 31 May 2015; Accepted 4 June 2015

Academic Editor: Anastasios Koulaouzidis

Copyright © 2015 Yaqin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Heintges and J. R. Wands, “Hepatitis C virus: epidemiology and transmission,” Hepatology, vol. 26, no. 3, pp. 521–526, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Rodriguez-Luna and H. E. Vargas, “Management of hepatitis C virus infection in the setting of liver transplantation,” Liver Transplantation, vol. 11, no. 5, pp. 479–489, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Guillouche and C. Féray, “Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation,” Alimentary Pharmacology & Therapeutics, vol. 33, no. 2, pp. 163–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Bahr and M. P. Manns, “Changing faces—natural course and treatment of hepatitis C after liver transplantation,” Journal of Hepatology, vol. 40, no. 4, pp. 699–701, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Charlton and R. Wiesner, “Natural history and management of hepatitis C infection after liver transplantation,” Seminars in Liver Disease, vol. 24, no. 2, pp. 79–88, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Forman, J. D. Lewis, J. A. Berlin, H. I. Feldman, and M. R. Lucey, “The association between hepatitis C infection and survival after orthotopic liver transplantation,” Gastroenterology, vol. 122, no. 4, pp. 889–896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Samuel, X. Forns, M. Berenguer et al., “Report of the monothematic EASL conference on liver transplantation for viral hepatitis: (Paris, France, January 12-14, 2006),” Journal of Hepatology, vol. 45, no. 1, pp. 127–143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Berenguer, M. Prieto, J. M. Rayón et al., “Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation,” Hepatology, vol. 32, no. 4, pp. 852–858, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. F. P. Picciotto, G. Tritto, A. G. Lanza et al., “Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation,” Journal of Hepatology, vol. 46, no. 3, pp. 459–465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Samuel, T. Bizollon, C. Feray et al., “Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study,” Gastroenterology, vol. 124, no. 3, pp. 642–650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Berenguer, “Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin,” Journal of Hepatology, vol. 49, no. 2, pp. 274–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Castells, V. Vargas, H. Allende et al., “Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation,” Journal of Hepatology, vol. 43, no. 1, pp. 53–59, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Chalasani, C. Manzarbeitia, P. Ferenci et al., “Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials,” Hepatology, vol. 41, no. 2, pp. 289–298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Berenguer, A. Palau, V. Aguilera, J. M. Rayón, F. S. Juan, and M. Prieto, “Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation,” American Journal of Transplantation, vol. 8, no. 3, pp. 679–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Crippin, T. McCashland, N. Terrault, P. Sheiner, and M. R. Charlton, “A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation,” Liver Transplantation, vol. 8, no. 4, pp. 350–355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Forns, M. García-Retortillo, T. Serrano et al., “Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation,” Journal of Hepatology, vol. 39, no. 3, pp. 389–396, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Thomas, J. J. Brems, G. Guzman-Hartman, S. Yong, P. Cavaliere, and D. H. Van Thiel, “Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation,” Liver Transplantation, vol. 9, no. 9, pp. 905–915, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. G. T. Everson, J. Trotter, L. Forman et al., “Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy,” Hepatology, vol. 42, no. 2, pp. 255–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. B. Jain, B. Eghtesad, R. Venkataramanan et al., “Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection,” Liver Transplantation, vol. 8, no. 11, pp. 1007–1013, 2002. View at Publisher · View at Google Scholar · View at Scopus